
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corporation is projected to experience significant revenue growth, with Corneal Health expected to advance by 9.4% for FY26, particularly in the latter half of the year as reimbursement for Epioxa improves. The company's innovative iDose pharmaceutical implant is seeing increased sales, contributing to a gross margin of 85.1%, which reflects an improvement of 280 basis points year-over-year and surpasses market expectations. Additionally, revenue from the iStent platform is estimated to have risen approximately 7% year-over-year, reinforcing Glaukos's positive financial outlook with revised revenue estimates of $205 million for FY26, driven by the anticipated growth in repeat administration patients for its products.
Bears say
Glaukos Corporation reported robust domestic glaucoma revenue of $86 million, which outperformed consensus expectations, and showcased a substantial year-over-year growth of 54%. However, the company has lowered its sales growth projections due to increasing challenges in the minimally invasive glaucoma surgery (MIGS) market internationally and a deceleration in U.S. growth, alongside revised adjusted earnings per share forecasts for 2026 and 2027 reflecting expected losses. Concerns regarding the potential for slower market adoption of its products, heightened competition, and possible unfavorable changes in the reimbursement landscape contribute to a pessimistic outlook for the firm's financial performance.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares